At week 12, participants who received placebo were reassigned to upadacitinib daily.The benefit of upadacitinib was measured by comparing the proportion of participants treated with upadacitinib who achieved an American College of Rheumatology 20 (ACR20) response at week 12 or week 14 to the proportion of participants treated with MTX or placebo who achieved an ACR20 response. ACR20 is a 20% improvement in signs and symptoms of RA.Upadacitinib was approved for medical use in the European Union in December 2019. Research
Upadacitinib has also demonstrated success in treating moderate to severe atopic dermatitis and has been found to have superior efficacy compared with placebo and dupilumab. References
External links
"Upadacitinib". Drug Information Portal. U.S. National Library of Medicine.
6-TGN are cytotoxic to cells by: (1) incorporation into DNA during the synthesis phase (S-phase) of the cell; and (2) through inhibition of the GTP-binding protein (G protein) Rac1, which regulates the Rac/Vav pathway. Chemistry
It is a pale yellow, odorless, crystalline powder. Names
Tioguanine (INN, BAN, AAN), or thioguanine (USAN). Thioguanine is administered by mouth (as a tablet – Lanvis). References
Further reading
Dean L (2012). "Thioguanine Therapy and TPMT Genotype". In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520351. Bookshelf ID: NBK100663. External links
"Tioguanine". Drug Information Portal. U.S. National Library of Medicine.